LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
Farzaneh Atashrazm,1 Nicolas Dzamko2 1Neuroscience Research Australia, Randwick; 2School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia Abstract: Major advances in understanding how genetics underlies Parkinson’s disease (PD) have provid...
Enregistré dans:
| Auteurs principaux: | Atashrazm F, Dzamko N |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2016
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/f5632c429f854b89b5083f7a96af03fd |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
TFEB Dependent Autophagy-Lysosomal Pathway: An Emerging Pharmacological Target in Sepsis
par: Xin Liu, et autres
Publié: (2021) -
Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine
par: Sahar M. El‑Haggar, et autres
Publié: (2022) -
Intestinal Macrophage Autophagy and its Pharmacological Application in Inflammatory Bowel Disease
par: Yang Zheng, et autres
Publié: (2021) -
The Secrets of Alternative Autophagy
par: Kaja Urbańska, et autres
Publié: (2021) -
Discovery of a small molecule inhibitor of cullin neddylation that triggers ER stress to induce autophagy
par: Yanan Li, et autres
Publié: (2021)